M. Mall (Berlin, Germany), N. Regamey (Lucerne, Switzerland), L. Naehrlich (Giessen, Germany), A. Shawcross (Manchester (Greater Manchester), United Kingdom)
In vitro activity of colistin in combination with N-acetylcysteine against Pseudomonas aeruginosa L. Pallecchi (Siena, Italy), S. Pollini (Florence, Italy), T. Di Maggio (Siena, Italy), D. Girelli (Milan, Italy), A. Teri (Milan, Italy), L. Cariani (Milan, Italy), S. Aliberti (Milan, Italy), F. Blasi (Milan, Italy), F. Sergio (Bresso, Italy), G. Rossolini (Florence, Italy)
|  |
Exhaled breath analysis by ion mobility spectrometry in children with asthma and cystic fibrosis M. Bannier (Maastricht, Netherlands), K. Van De Kant (Maastricht, Netherlands), J. Baumbach (Reutlingen, Germany), Q. Jobsis (Maastricht, Netherlands), E. Dompeling (Maastricht, Netherlands), S. Barnowski (sandra.barnowski@dbmr.unibe.ch / Department for Biomedical Research, B. University Hospital, B. , C. , A. Stokes (Andrea.Stokes@insel.ch / Department for Biomedical Research, B. University Hospital, B. , C. , T. Geiser (Thomas.Geiser@insel.ch / Department for Biomedical Research, B. University Hospital, B. , C. , L. Knudsen (knudsen.lars@mh-hannover.de / Functional and Applied Anatomy Medical School Hannover,Hannover), M. Funke-Chambour (Manuela.Funke-Chambour@insel.ch / Department for Biomedical Research, B. University Hospital, B. , C.
|  |
Antibodies against Pseudomonas aeruginosa in patients with cystic fibrosis – clinical application G. Petrova (Sofia, Bulgaria), P. Perenovska (Sofia, Bulgaria), S. Lesichkova (Sofia, Bulgaria), S. Lazova (Sofia, Bulgaria), D. Miteva (Sofia, Bulgaria), K. Cholakova (Sofia, Bulgaria), T. Strateva (Sofia, Bulgaria)
|  |
Induction of innate immune response in fresh human lung tissue ex vivo following P. aeruginosa infection L. Mueller (Hannover, Germany), N. Kraemer (Hannover, Germany), P. Braubach (Hannover, Germany), D. Jonigk (Hannover, Germany), H. Fieguth (Hannover, Germany), O. Pfennig (Hannover, Germany), C. Bersch (Hannover, Germany), A. Braun (Hannover, Germany), K. Sewald (Hannover, Germany), S. Wronski (Hannover, Germany)
|   |
Association of HLA-DR alleles with pulmonary cystic fibrosis E. Mortaz (Tehran, Islamic Republic of Iran), A. Asef (Tehran, Islamic Republic of Iran), H. Ghaffaripour (Tehran, Islamic Republic of Iran), I. Adcock (Tehran, Islamic Republic of Iran)
|  |
Effectiveness of mechanical insufflation-exsufflation device in pediatric patients with cystic fibrosis a. fakharian (tehran, Islamic Republic of Iran), S. Karimzade (tehran, Islamic Republic of Iran), M. Abedi (tehran, Islamic Republic of Iran), S. Kharabian Masouleh (tehran, Islamic Republic of Iran), L. Shordel (tehran, Islamic Republic of Iran), S. Khalilzadeh (tehran, Islamic Republic of Iran)
|  |
Oxygen uptake kinetics in walking children with cystic fibrosis Y. Combret (Le Havre, France), C. Médrinal (Le Havre, France), G. Prieur (Le Havre, France), A. Robledo Quesada (Le Havre, France), P. Le Roux (Le Havre, France), G. Reychler (Bruxelles, Belgium)
|   |
Home monitoring of respiratory rate from pulse oximetry in children with cystic fibrosis D. Wertheim (Kingston upon Thames, United Kingdom), C. Olden (Brighton, United Kingdom), L. Symes (Brighton, United Kingdom), C. Edmondson (London, United Kingdom), J. Davies (London, United Kingdom), K. Brownlee (London, United Kingdom), P. Seddon (Brighton, United Kingdom)
|  |
Evaluation of user behaviour with an Oscillating Positive Expiratory Pressure (OPEP) device in paediatric cystic fibrosis patients. K. O'Sullivan (Limerick, Ireland), L. O'Sullivan (Limerick, Ireland), C. Dunne (Limerick, Ireland), D. Mcgrath (Limerick, Ireland), B. Linnane (Limerick, Ireland)
|   |
What is a NICE definition of lung disease in patients with Cystic Fibrosis and its impact on treatment? G. Dick (Newcastle upon Tyne, United Kingdom), S. Bourke (Newcastle upon Tyne, United Kingdom), C. Echevarria (Newcastle upon Tyne, United Kingdom), S. Doe (Newcastle upon Tyne, United Kingdom)
|   |
Comparative Evaluation of Clinical, Spiro/Oscillometric and Tomographic Parameters As A Global Assessment of Children With Cystic Fibrosis E. Toprak Kanik (Manisa, Turkey), O. Yilmaz (Manisa, Turkey), A. Kanik (Izmir, Turkey), E. Ozdogru (Izmir, Turkey), Y. Simsek (Manisa, Turkey), H. Alper (Izmir, Turkey), H. Yuksel (Manisa, Turkey)
|  |
The effect of spirometry on multiple breath washout outcomes in children with cystic fibrosis J. Au (Toronto, Canada), R. Mcdonald (Toronto, Canada), S. Stanojevic (Toronto, Canada), F. Ratjen (Toronto, Canada)
|   |
Does the lung clearance index track from preschool to school age in children with cystic fibrosis? M. Klingel (Toronto, Canada), S. Isaac (Toronto, Canada), S. Stanojevic (Toronto, Canada), R. Jensen (Toronto, Canada), M. Solomon (Toronto, Canada), H. Grasemann (Toronto, Canada), V. Waters (Toronto, Canada), N. Sweezey (Toronto, Canada), S. Davis (Indianapolis, United States of America), F. Ratjen (Toronto, Canada)
|  |
Does physiotherapy affect Lung Clearance Index in Cystic Fibrosis patients ? E. Hatziagorou (Thessaloniki, Greece), E. Kouroukli (Thessaloniki, Greece), M. Parisi (Thessaloniki, Greece), F. Kirvassilis (Thessaloniki, Greece), P. Peftoulidou (Thessaloniki, Greece), I. Mouratidou (Thessaloniki, Greece), J. Tsanakas (Thessaloniki, Greece)
|  |
A music therapy intervention as an adjunct to chest physiotherapy in children with cystic fibrosis J. Perez Frias (Malaga, Spain), A. Montero-Ruiz (Malaga, Spain), L. Fuentes Galvez (Malaga, Spain), E. Perez-Ruiz (Malaga, Spain), M. Diaz Huelamo (Malaga, Spain), E. Martin-MontañEz (Malaga, Spain)
|   |
Early renal involvement in children with cystic fibrosis. W. Shahin (Cairo, Egypt), A. Badr (Cairo, Egypt), W. Rabie (Cairo, Egypt), R. Ahmed (Cairo, Egypt), M. Mohsen (Cairo, Egypt), M. El-Falaki (Cairo, Egypt)
|   |
Newborn Screening for Cystic Fibrosis in Wales over 20 years. Changes in incidence dependent on screening protocol I. Doull (CCCCardiffCCardiff, United Kingdom), C. Course (Cardiff, United Kingdom), R. Hanks (Cardiff, United Kingdom), S. Moat (Cardiff, United Kingdom)
|   |
Newborn screening for Cystic Fibrosis over 20 years and the identification of affected not detected infants. I. Doull (Cardiff, United Kingdom), R. Hanks (Cardiff, United Kingdom), C. Course (Cardiff, United Kingdom), S. Moat (Cardiff, United Kingdom)
|   |